InvestorsHub Logo
Followers 2
Posts 188
Boards Moderated 0
Alias Born 01/09/2019

Re: None

Wednesday, 02/01/2023 3:33:16 PM

Wednesday, February 01, 2023 3:33:16 PM

Post# of 575
The initiation of the APTIVATE trial raises a serious question. The r/rAML patients are in desperate straits. Given a choice between an RP2D dose of LUXP (which has shown multiple CRs) and a finding dose of G3 Lux which would you choose. I believe that both need to be offered for ethical reasons. i.e. is APTO going to have trouble establishing an RP2D for G3 Lux?

We should have cleared the G3 Lux 50mg dose by now.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent APTO News